{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:15Z","timestamp":1790286915802,"version":"4.1.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/dad.0000000000000023","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T23:31:21Z","timestamp":1401751881000},"page":"493-497","source":"Crossref","is-referenced-by-count":51,"title":["Panniculitis in Patients Treated With BRAF Inhibitors"],"prefix":"10.1097","volume":"36","author":[{"given":"Bonita","family":"Choy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Anforth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fern\u00e1ndez-Pe\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210202","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":". Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-7-20210202","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":". Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R3-7-20210202","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":". Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"issue":"suppl 15","key":"R4-7-20210202","doi-asserted-by":"crossref","first-page":"e19017","DOI":"10.1200\/jco.2012.30.15_suppl.e19017","article-title":". Cutaneous side effects (cAE) of vemurafenib (V): single-center cohort study of 28 metastatic melanoma (mM) patients (pts).","volume":"30","author":"Goldinger","year":"2012","journal-title":"J Clin Oncol"},{"key":"R5-7-20210202","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1001\/archdermatol.2012.2649","article-title":". Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy.","volume":"148","author":"Haenssle","year":"2012","journal-title":"Arch Dermatol"},{"key":"R6-7-20210202","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":". Cutaneous effects of BRAF inhibitor therapy: a case series.","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"R7-7-20210202","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":". Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"R8-7-20210202","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":". Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"R9-7-20210202","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CMR.0b013e3283570792","article-title":". Vemurafenib-induced neutrophilic panniculitis.","volume":"22","author":"Monfort","year":"2012","journal-title":"Melanoma Res"},{"key":"R10-7-20210202","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cup.12149","article-title":"Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.","volume":"40","author":"Kim","year":"2013","journal-title":"J Cutan Pathol"},{"key":"R11-7-20210202","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/PAT.0b013e328359d5e2","article-title":". Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.","volume":"44","author":"Dabner","year":"2012","journal-title":"Pathology"},{"key":"R12-7-20210202","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/jcp.2008.058289","article-title":"Drug-induced cutaneous pathology.","volume":"62","author":"Ramdial","year":"2009","journal-title":"J Clin Pathol"},{"key":"R13-7-20210202","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1046\/j.1525-1470.2001.01969.x","article-title":"Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy.","volume":"18","author":"Prendiville","year":"2001","journal-title":"Pediatr Dermatol"},{"key":"R14-7-20210202","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.annder.2010.11.009","article-title":". Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib.","volume":"138","author":"de Masson","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"R15-7-20210202","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaad.2005.03.001","article-title":"Subcutaneous Sweets syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis.","volume":"52","author":"Cohen","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R16-7-20210202","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1600-0560.2009.01196.x","article-title":". Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.","volume":"36","author":"Becherer","year":"2009","journal-title":"J Cutan Pathol"},{"key":"R17-7-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":". Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"R18-7-20210202","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":". Inhibition of mutated, activated BRAF in metastatic melanoma.","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"R19-7-20210202","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":". Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"R20-7-20210202","first-page":"1020","article-title":". BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600EK) metastatic melanoma.","volume":"24","author":"Trefzer","year":"2011","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000000023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:56:50Z","timestamp":1620950210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000372-201406000-00007"}},"subtitle":["A Case Series"],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000000023","relation":{},"ISSN":["0193-1091"],"issn-type":[{"value":"0193-1091","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}